Pipeline
Click on bar or (i) in the in pipeline for more information
| Alnylam 5x15 Programs | Licensed programs |  ABOUT OUR PARTNERS |
||
| Partner Programs |
- Development Programs
-
Programs Discovery Development Phase I Phase II Phase III TTR Amyloidosis Hemophilia PCSK9/Hypercholesterolemia Hepcidin/Refractory Anemia Hemoglobinopathy RSV InfectionLiver Cancers - Licensed Programs
-
Programs Discovery Development Phase I Phase II Phase III Diabetic Macular EdemaAcute Kidney InjurySolid TumorsHypercholesterolemiaSolid TumorsHepatitis CJC Virus / PMLNovartis ProgramsOncology, MetabolicImmuno-InflammatoryHeart Failure/FibrosisSolid TumorsSolid TumorsMalaria
| Alnylam 5x15 Programs | Licensed programs | ABOUT OUR PARTNERS |
||
| Partner Programs |
TTR Amyloidosis
ALN-TTR, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR amyloidosis.
Hemophilia
ALN-APC is a systemically delivered RNAi therapeutic targeting protein C, a genetically defined target.
PCSK9/Hypercholesterolemia
ALN-PCS is an RNAi therapeutic, being developed to treat hypercholesterolemia, or high levels of cholesterol in the blood.
Hepcidin/Refractory Anemia
ALN-HPN is a new development program, comprising a systemic RNAi therapeutic targeting hepcidin, a genetically defined gene in iron homeostasis, for the treatment of refractory anemia.
Hemoglobinopathy
ALN-TMP, an RNAi therapeutic targeting Tmprss6 for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia.
RSV Infection
The Phase IIb trial is a multi-center, global, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients with a primary endpoint of a reduction in incidence of new or progressive BOS.
Liver Cancers
We have advanced our RNAi therapeutic, ALN-VSP, into the clinic for the treatment of liver cancers and potentially other solid tumors with liver involvement. The Phase I study showed that ALN-VSP was generally well tolerated.
Diabetic Macular Edema
Quark received an InterfeRX license to develop RNAi therapeutics targeting RTP801, a gene implicated in ocular diseases. The RTP801 program is a partnership between Quark and Pfizer.
Acute Kidney Injury
Quark received an InterfeRx license to develop RNAi therapeutics targeting the p53 gene for renal failure.
Solid Tumors
Calando received an InterfeRx license to develop RNAi therapeutics for RRM2, a cancer target.
Hypercholesterolemia
Tekmira received an InterfeRx license to develop RNAi therapetics targeting the apoB gene for the treatment of hypercholesterolemia.
Solid Tumors
Tekmira received an InterfeRx license to develop RNAi therapetics targeting the PLK1 gene, a cancer target.
Hepatitis C
Regulus is developing a microRNA therapeutic targeting miR-122 for the treatment of HCV infection.
JC Virus / PML
PML is caused by infection of the central nervous system with a virus called "JC virus" and can occur in certain immune-suppressed patients, including those receiving immunomodulatory therapies.
Novartis Programs
Alnylam and Novartis Institute for BioMedical Research (NIBR) will discover, develop and commercialize RNAi therapeutics across multiple therapeutic areas in Novartis' research portfolio.
Oncology, Metabolic
Takeda is developing RNAi therapeutics for oncology and metabolic disease targets.
Immuno-Inflammatory
GSK and Regulus Therapeutics formed the first ever microRNA-focused strategic alliance to develop microRNA-targeted therapeutics.
Heart Failure/Fibrosis
Regulus is researching the role of microRNA, known as miR-21, in heart failure and fibrosis.
Solid Tumors
Calando received an InterfeRx license for the HIF-2α cancer gene target.
Solid Tumors
GeneCare received an InterfeRx license to develop RNAi therapeutics directed against two DNA helicase genes associated with cancer.
Malaria
Cenix is researching potential RNAi therapeutics for the silencing of multiple disease targets for the treatment of malaria infection.
The ALN-RSV program is partnered in Asia with Kyowa Hakko Kirin and in the rest of the world with Cubist Pharmaceuticals
Alnylam expects to partner its ALN-VSP program prior to initiating a Phase II clinical study.
Quark received an InterfeRX license to develop RNAi therapeutics targeting RTP801, a gene implicated in ocular diseases. The RTP801 program is a partnership between Quark and Pfizer.
Quark received an InterfeRx license to develop RNAi therapeutics targeting the p53 gene for renal failure.
Calando received an InterfeRx license to develop RNAi therapeutics for RRM2, a cancer target.
Tekmira received an InterfeRx license to develop RNAi therapetics targeting the apoB gene for the treatment of hypercholesterolemia.
Tekmira received an InterfeRx license to develop RNAi therapetics targeting the PLK1 gene, a cancer target.
Regulus is developing a microRNA therapeutic targeting miR-122 for the treatment of HCV infection.
Alnylam and Biogen Idec will initially conduct investigative research into the potential of using RNAi technology to develop therapeutics to treat PML.
Alnylam and Novartis Institute for BioMedical Research (NIBR) will discover, develop and commercialize RNAi therapeutics across multiple therapeutic areas in Novartis' research portfolio.
Takeda is developing RNAi therapeutics for oncology and metabolic disease targets.
GSK and Regulus Therapeutics formed the first ever microRNA-focused strategic alliance to develop microRNA-targeted therapeutics.
Regulus is researching the role of microRNA, known as miR-21, in heart failure and fibrosis.
Calando received an InterfeRx license for the HIF-2α cancer gene target.
GeneCare received an InterfeRx license to develop RNAi therapeutics directed against two DNA helicase genes associated with cancer.
Cenix is researching potential RNAi therapeutics for the silencing of multiple disease targets for the treatment of malaria infection.
